Phase 1 clinical data on first-in-class HIV-1 maturation inhibitor, PA-457.
D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017321:Clinical Trials, Phase I as Topic; D004305:Dose-Response Relationship, Drug; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development*; D006801:Humans; D008297:Male; D012016:Reference Values; D013386:Succinates / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014315:Triterpenes / Q000008:administration & dosage / Q000493:pharmacokinetics*; D053978:Pentacyclic Triterpenes
D019380:Anti-HIV Agents; D013386:Succinates; D014315:Triterpenes; C479935:bevirimat; D053978:Pentacyclic Triterpenes